Dashboard
Manage Tickers

KPTIKaryopharm Therapeutics Inc.

Nasdaq karyopharm.com


$ 1.07 $ 0.00 (0 %)    

Friday, 26-Apr-2024 15:58:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.06
$ 1.09
$ 0.00 x 0
$ 0.00 x 0
$ 1.02 - $ 1.09
$ 0.62 - $ 3.87
660,736
na
121.07M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-02-2023 09-30-2023 10-Q
3 08-02-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-17-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-03-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-24-2021 12-31-2020 10-K
14 11-02-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 02-26-2020 12-31-2019 10-K
18 11-04-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-15-2018 12-31-2017 10-K
26 11-02-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-15-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-13-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

karyopharm-announces-presentations-in-endometrial-cancer-and-myelofibrosis-at-the-2024-american-society-of-clinical-oncology-annual-meeting
Karyopharm Announces Presentations In Endo...
04/24/2024 20:42:32

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"...

onco360-selected-as-the-preferred-national-specialty-pharmacy-partner-for-karyopharms-product-xpovio-a-first-in-class-xpo-1-inhibitor
Onco360 Selected As The Preferred National...
03/13/2024 20:38:15

Onco360®, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Ka...

hc-wainwright--co-maintains-buy-on-karyopharm-therapeutics-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on Karyo...
03/01/2024 12:10:52

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...

karyopharm-sees-2024-total-revenue-140m-160m-vs-15202m-est
Karyopharm Sees 2024 Total Revenue $140M-$...
02/29/2024 12:31:56

karyopharm-therapeutics-q4-2023-gaap-eps-036-misses-030-estimate-sales-3375m-miss-3540m-estimate
Karyopharm Therapeutics Q4 2023 GAAP EPS $...
02/29/2024 12:31:15

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimat...

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

karyopharm-therapeuticss-earnings-a-preview
Karyopharm Therapeutics's Earnings: A Preview
02/28/2024 19:01:25

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
02/06/2024 17:31:29

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
02/05/2024 17:31:04

watching-karyopharm-therapeutics-traders-circulate-analyst-comments-suggesting-with-the-mor-takeover-interest-a-larger-cancer-company-could-also-be-interested-in-acquiring-kpti-for-selinexor
Watching Karyopharm Therapeutics; Traders ...
02/05/2024 17:23:25

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/05/2024 13:06:14

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
01/31/2024 21:31:06

karyopharm-expects-preliminary-unaudited-full-year-2023-total-revenue-of-146m-vs-15003m-est-expects-prelim-q4-revenue-336m-vs-3764m-est
Karyopharm Expects Preliminary Unaudited F...
01/08/2024 13:59:15

karyopharm-shares-data-at-ash-2023-showing-strong-svr-and-tss-durability-observed-from-phase-1-study-of-selinexor-60mg-and-ruxolitinib-in-jak-inhibitor-jaki-nave-myelofibrosis-patients
Karyopharm Shares Data At ASH 2023 Showing...
12/11/2023 06:40:27

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggesti...

karyopharm-therapeutics-announced-the-presentation-of-updated-long-term-safety-efficacy-data-from-a-pre-specified-exploratory-subgroup-analysis-of-siendo-study-in-patients-with-advanced-or-recurrent-tp53-wild-type-endometrial-cancer
Karyopharm Therapeutics Announced The Pres...
11/06/2023 12:19:25

piper-sandler-maintains-overweight-on-karyopharm-therapeutics-lowers-price-target-to-5
Piper Sandler Maintains Overweight on Kary...
11/03/2023 21:16:24

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the p...

rbc-capital-maintains-outperform-on-karyopharm-therapeutics-lowers-price-target-to-3
RBC Capital Maintains Outperform on Karyop...
11/03/2023 18:56:22

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price ta...

karyopharm-maintains-fy-2023--revenue-guidance-of-145m-160m-consensus-of-15131m--including-us-xpovio-net-product-revenue-guidance-of-110m-125m
Karyopharm Maintains FY 2023 Revenue Guid...
11/02/2023 11:37:56

karyopharm-therapeutics-q3-eps-030-misses-028-estimate-sales-3601m-miss-3728m-estimate
Karyopharm Therapeutics Q3 EPS $(0.30) Mis...
11/02/2023 11:36:25

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimat...

earnings-scheduled-for-november-2-2023
Earnings Scheduled For November 2, 2023
11/02/2023 08:56:34

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION